Histone deacetylase inhibitors as immunomodulators in cancer therapeutics

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• Histone deacetylase inhibitors (HDACIs) are anticancer agents targeting gene expression via chromatin modification.
• HDACIs exhibit cytotoxic and cytostatic effects on tumor cells, with established clinical development.
• Emerging evidence highlights potent immunomodulatory activities of HDACIs in preclinical and clinical cancer studies.

Purpose of the Study:

• To summarize recent findings on HDACIs' effects on tumor cell immunogenicity.
• To review the impact of HDACIs on various components of the host immune system.
• To discuss the complex and context-dependent immunomodulatory activities of HDACIs.

Main Methods:

• Literature review of preclinical and clinical studies on HDACIs.
• Analysis of data on HDACIs' effects on tumor cells and immune cells.
• Synthesis of information regarding class-specific and setting-dependent HDACIs' activities.

Main Results:

• HDACIs modulate tumor cell immunogenicity and interact with multiple immune system components.
• The immunomodulatory effects of HDACIs are intricate and vary based on HDACIs class specificity.
• Experimental settings and targeted immune cell populations significantly influence HDACIs' immunomodulatory outcomes.

Conclusions:

• HDACIs possess significant immunomodulatory potential for cancer immunotherapy.
• Understanding the nuances of HDACIs' immune effects is crucial for optimizing their therapeutic application.
• Further research is warranted to elucidate the complex interplay between HDACIs, tumor cells, and the immune system.